Mahamaya Lifesciences Ltd Financials
Company Logo

Mahamaya Lifesciences Ltd Financial Statement

Mahamaya Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Mahamaya Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual265.75
Operating Expenses Annual241.19
Operating Profit Annual25.87
Interest Annual6.83
Depreciation1.77
Net Profit Annual12.82
Tax Annual4.44

Mahamaya Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning1.09
Cash Flow from Operations-3.35
Cash Flow from Investing-4.43
Cash Flow from Financing8.47
Cash Flow at the End1.78

Mahamaya Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)9.73
PBIT Margin (%)9.07
PBT Margin (%)7.74
Net PROFIT Margin (%)4.82
Return On Networth / Equity (%)34.16
Return On Networth /Employed (%)25.56
Return On Assets (%)13.60
Total Debt / Equity (X)1.50
Asset Turnover Ratio (%)2.82

Mahamaya Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual31.17
Total Current Assets Annual157.04
Non Current Assets Annual31.67
Total Shareholders Funds Annual49.87
Total Assets Annual188.71

Mahamaya Lifesciences Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

0.00

Surprise

0.00%

FAQS on Mahamaya Lifesciences Ltd Financials

As of Nov 18, 2025, Mahamaya Lifesciences Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Mahamaya Lifesciences Ltd is not with a debt-to-equity ratio of 2.16.

In FY 2024 , Mahamaya Lifesciences Ltd recorded a total revenue of approximately 161.52 Cr marking a significant milestone in the company's financial performance.

Mahamaya Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.3% annually, respectively..

Mahamaya Lifesciences Ltd's current PE ratio is .

Mahamaya Lifesciences Ltd's ROCE averaged 16.4% from the FY ending March 2022 to 2024, with a median of 16.3%. It peaked at 17.7% in March 2023, reflecting strong capital efficiency over the period..

Mahamaya Lifesciences Ltd's latest EBIT is Rs. 12.94 Cr, surpassing the average EBIT of Rs. 8.70 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions